Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Haematology > Clotting > Flashcards

Clotting Flashcards

1
Q

Glycoproteins provide phospholipid surface for platelets to stick to. Describe 3 glycoproteins that facilitate this step and what they bind to [3]
What other component of the blood assists in platelet adhesion?

A

Gp 1a/2a + 6 bind directly to exposed collagen
GP 1b bind to vWF, indirectly to collagen
GP 2b/3a bind to Fibrinogen
VWF assists inplatelt adhesion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

After a platelet plug is formed, we then form a fibrin clot. What causes this? [2]
Whats the difference between primary hemostatic plug and definitive hemostasis [2]

A

Activation of coagulation factors by physiological activator e.g. Tissue Factor
These activate each other in a cascade like dominos.
When the primary hemostatic plug forms, its still a weak clot - only fibrinogen adheres
Definitive hemostasis is when fibrin forms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the final steps in the coagulation cascade

A

Prothrombin cleaved to Thrombin

Its then cleaves Fibrinogen to Fibrin which forms the clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe 3 natural anti-coagulants and their function

A

Overall function: confine clot formation
TFPI - switches off factors 7a and 10a

Proteins C + S - Switch off 5 and 8a, reducing thrombin production

Anti-thrombin - Switches of 5, 8 , 9, 10, 11, thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What triggers fibrinolysis?

[3]

A

Endothelial cells releasing plasminogen activators (t-PA, u-PA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What do Tissue Plasminogen Activators do?

A

They cleave plasminogen into plasmin allowing fibrinolysis to occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What do we test for in a D-dimer? [1]

A

Fibrin Degradation Products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anti-thrombotic drugs include antiplatelets and anticoagulants.
Anti-platelets act in 3 pathways. Give examples of each.

A
  • Target adhering Gylcoproteins eg Abciximab
  • Target surface receptors eg Clopidogrel, prasugrel, Ticagrelor
  • Inhibition of COX pathway preventing AA> TXA2, prevents platelet aggregation eg aspirin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Warfarin is a common anti-coagulant what does it do? [3]

A
  • Inhibits epoxide reductase, prevents reduction of vitamin K (Vitamin K antagonist)
  • Prevents coagulation cascade
  • Reduces conc of various clotting factors inc 2, 7, 9, 10 and prothrombin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Other anti-coagulants include heparins and DOACs, what are their MOAs? Give 2 examples of DOACs

A

Heparins inhibit thrombin

Direct Oral AntiCoagulants:

1) Rivaroxaban inhibits factor Xa
2) Dabigatran inhibits thrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Endothelium produces a variety of substances in a physiological state in a blood vessel. What are these substances that cause endothelium to act as a non-stick pan? [5]

A 
Heparans
TFPI - tissue factor pathway inhibitor
Thrombomodulin
Prostacyclin
NO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Vessel damage results in platelet adhesion: 3 steps

Describe the last 2 steps

A

Platelets adhere, activate and aggregate
Platelet activation - platelets release ADP, thromboxane A2 and serotonin which attract more platelets causing…
Platelet aggregation - platelet plug formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What inhibits t-PA and u-PA? [2]
What inactivates plasmin [3]
Describe TAFI

A

Regulators:
Inhibitors of plasminogen t-PA and u-PA: PAI-1 and PAI-2
Inhibitors of plasmin - alpha2-antiplasmin, alpha2-macroglobulin
Thrombin activatable fibrinolysis inhibitor (TAFI) which modifies fibrin to make it more resistant to t-PA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Warfarin
Indications [3]
Side effects

A

Indications

  • VTE
  • AF
  • Mechanical heart valves

SE

  • Hemorrhage
  • Teratogenic
  • Skin necrosis
  • Purple toes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does skin necrosis occur as a side effect in warfarin?

How can it be avoided?

A

synthesis of protein C reduced at first when started causing temporary pro-coagulant state (normally avoided by concurrent heparin administration) so thrombosis across venules leads to skin necrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Warfarin: interactions
Potentiators [8]
Reduce effects [3]

A 
P450 enzyme inhibitors - potentiate effect
Ciprofloxacin, erythromycin
	Omeprazole 
	Amiodarone 
	Allopurinol 
	Ketoconazole, fluconazole
	Sertraline, Fluoxetine 
	Sodium valproate 
	Acute alcohol intoxication 
P450 enzyme inducers - reduce effect
	Phenytoin, Carbamazepine, Phenobarbitone 
	St John’s wort 
 Chronic alcohol intake 
	Smoking (affects CVP1A2)
17
Q

Advise going on warfarin [2]

A
  • monitored by INR

- long half-life means takes a number of days to achieve a stable INR

18
Q

Management of high INR:

  • Major bleeding [3]
  • INR >8 with minor bleeding [3]
A

 Major bleeding:

STOP warfarin and give IV VITAMIN K 5mg and PROTHROMBIN COMPLEX CONCENTRATE (FFP if not available)

 INR>8 and minor bleeding:

STOP warfarin and give IV VITAMIN K 1-3mg (repeat dose after 24h if INR still too high); restart WARFARIN when INR <5

19
Q

Management of INR 5-8 and no bleeding [2]

A

 INR 5-8 and no bleeding: WITHOLD 1-2 doses of warfarin and then reduce subsequent maintenance dose

20
Q

Antithrombin activators are another form of anticoagulant medications. Describe their MOA
Give 4 examples

A

Activates antithrombin III to form a complex [1] that inhibits thrombin, factors Xa, IXa, Xia and XIIa [1]

Eg: heparin, LMWH
Enoxaparin, dalteparin, fondaparinux

21
Q

In what situation would heparin [2] and LMWH [2] be indicated

A

o Heparin: situations where high risk of bleeding as anticoagulation can be terminated rapidly, renal failure
o LMWH: VTE treatment and prophylaxis, ACS

22
Q

Complications of Antithrombin activators [2]

A

Active bleeding

Bacterial endocarditis

23
Q

Antithrombin activators SE [6]

A 
Bleeding
Osteoporosis (lower risk with LMWH)
Heparin induced
Thrombocytopenia (lower risk with LMWH)
Hyperkalaemia
24
Q

What do you do for overdose reversal of heparins and LMWH

A

Protamine sulphate fully reverses effect of heparin

Partially reverses effects of LMWH

25
Q

Interactions [2]

A

NSAIDs, SSRIs, platelets

Increased bleeding risk

26
Q

MOA of aspirin [3]

Indications

A

COX inhibitor preventing TXA2 formation
Promotes platelet aggregation

Indications

  • Atherosclerotic disease secondary prevention
  • ACS
  • Suspected/actual TIA
27
Q

Aspirin SE [3]

Interactions [4]

A
  • Gastric erosions
  • Bronchospasm
  • Tinnitus

Interactions:

  • Increased bleeding risk with SSRIs
  • NSAIDs inhibit platelet action
  • Aspirin reduces methotrexate excretion
  • Toxicity with acetazolamide
28
Q

Dypyramidole
Indications [2]
SE [4]

A

Indicated:

  • Secondary stroke and TIA prevention
  • Anticoagulant adjunct in thromboembolism prophylaxis if prosthetic heart valve

SE:

  • GI upset
  • Vasodilation
  • Hemorrhage less common
  • Worsens IHD symptoms
29
Q

Reversal of dabigatran?

A

Idarucizumab

30
Q

What are indications of NOAC? [3]

A

Prevention of VTE following hip/knee surgery
Mx of DVT/PE
Prevention of stroke in non-valvular AF

31
Q

Comparing UH with LMWH

A

Standard heparin (mini-Hep)

  • Activates antithrombin III
  • Forms complex that inhibits thrombin, factors Xa, IXa, Xia and XIIa
  • RENAL failure
  • Short acting

LMWH

  • Only increases the action of antithrombin III on factor Xa
  • Cannot be used in renal failure
  • Long acting

Low molecular weight heparins are renally excreted and hence accumulate in severe renal impairment. While the doses recommended for prophylaxis
against DVT and prevention of thrombus formation in extracorporeal circuits are well tolerated in patients with ERF, the doses recommended for treatment of DVT and PE have been associated with severe, sometimes fatal, bleeding episodes in such patients. Hence the use of unfractionated heparin
would be preferable in these instances.

32
Q

Comparing monitoring in UH and LMWH

A

UH - APTT

LMWH - anti factor Xa monitored although not routinely monitored

33
Q

Heparin induced thrombocytopenia pathophysiology [2]

A

Immune mediated antibodies form against complexes of platelet factor 4 and heparin
Abs bind to PF4-heparin complexes on platelet surface and activate platelets

34
Q

HIT
Onset
Features
Treatment

A

usually does not develop until after 5-10 days of treatment
despite being associated with low platelets HIT is actually a prothrombotic condition
features include a greater than 50% reduction in platelets, thrombosis and skin allergy
treatment options include alternative anticoagulants such as lepirudin and danaparoid

Haematology (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions